UK-PBC Core Publications

  • Rice S, Albani V, Minos D, Fattakhova G, Mells GF, Carbone M, Flack S, Varvaropoulou N, Badrock J, Spicer A, Sandford RN, Shirley MDF, Coughlan D, Hirschfield G, Taylor-Robinson SD, UK-PBC Consortium, Vale L, Jones DEJ. Impact of Primary Biliary Cholangitis on Quality of Life and Health Care Costs in the UK. Clin Gastroenterol Hepatol 2021; 19:768-776
  • Barron-Millar B, Ogle L, Mells GM, Flack S, Badrock J, Sandford R, Kirby JA, Palmer JM, Jopson L, Brain J, Smith GR, Rushton S, Hegade VS, Jones R, Rushbrook S, Thorburn D, Ryder S, Hirschfield G, UK-PBC Research Consortium, Dyson JK, Jones DEJ. The Serum proteome and ursodeoxycholic acid response in primary biliary cholangitis. Hepatology 2021 In press.
  • Leighton J, Thain C, Mitchell-Thain R, Jones DEJ. Patient ownership of Primary Biliary Cholangitis long term management. Frontline Gastro 2021; In press
  • Phaw NA, Dyson JK, Mells G, Jones DEJ. Understanding fatigue in primary biliary cholangitis. Dig Dis Sci 2021; In press
  • Asselta R, Paraboschi EM, Gerussi A, Cordell HJ, Mells GF, Sandford RN, Jones DEJ, Nakamura M, Ueno K, Hitomi Y, Kawashima M, Nishida N, Tokunaga K, Nagasaki M, Tanaka A, Tang R, Li Z, Shi Y, Liu X, Xiong M, Hirschfield G, Siminovitch KA; Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium; Japan PBC-GWAS Consortium, Carbone M, Cardamone G, Duga S, Gershwin ME, Seldin MF, Invernizzi P. X chromosome contribution to the genetic architecture of primary biliary cholangitis. Gastroenterology 2021; In press
  • Montali L, Gragnano A, Miglioretti M, Frigerio A, Vecchio L, Gerussi A, Cristoferi L, Ronca V, D’Amato D, O’Donnell SE, Mancuso C, Lucà M, Yagi M, Reig A, Jopson L, Pilar S, Jones DEJ, Pares A, Mells G, Tanaka A, Carbone M, Invernizzi P. Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. J Transl Autoimmun 2021; In press
  • Carbone M, D’Amato D, Hirschfield GM, Jones DEJ, Mells GF. Histology is relevant for risk stratification in primary biliary cholangitis. Aliment Pharmacol Ther 2020; 51:192-193.
  • Hegade VS, Mells GF, Fisher H, Kendrick S, DiBello J, Gilchrist K, Alexander GJ, Hirschfield GM, Sandford RN, Jones DEJ. Pruritus in Primary Biliary Cholangitis Is Common and Under-treated: Results from 2194 patients in the UK-PBC Cohort. Clin Gastroenterol Hepatol 2019; 17:1379-1387.
  • Hegade VS, Pechlivanis A, McDonald JAK, Rees D, Corrigan M, Hirschfield GM, Taylor-Robinson SD, Holmes E, Marchesi JR, Kendrick S, Jones DEJ. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus. Liver Int 2019; 39:965-977
  • Etherington RE, Millar BJM, Innes BA, Jones DEJ, Kirby JA, Brain JG. Bile acid receptor agonists in primary biliary cholangitis: Regulation of the cholangiocyte secretome and downstream T cell Differentiation. FASEB BioAdvances. 2019; 1–12.
  • Alrubaiy L, Mells G, Flack S, Bosomworth H, Hutchings H, Williams J, Jones DEJ, UK-PBC Research Consortium. PBC-10: a short quality of life measure for clinical screening in primary biliary cholangitis. Aliment Pharmacol Ther 2019; 50:1223-1231
  • Martin ML, Stassek L, Blum SI, Joshi AV, Jones DEJ. Development and Adaptation of Patient-Reported Outcome Measures for Patients Who Experience Itch Associated With Primary Biliary Cholangitis. J Pat Report Outcomes 2019; 3:2.
  • Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Spicer A, Badrock J, Bernuzzi F, Ainsworth HF, Cardinale V, Heneghan MA, Thorburn D, Bathgate A, Jones R, Neuberger JM, Battezzati GM, Zuin M, Taylor-Robinson S, Donato M, Kirby J, Andreone P, Thain C, Floreani A, Sampaziotis F, Muratori L, Adgey C, Alvaro D, Jopson L, Andriulli A, Lim R, Galli A, Trembling P, Azzaroli F, Williamson K, Frugiuele, Rigamonti C, Marzioni M, Labbadia G, Miele L, Crocè L, Almasio P, Valenti L, Spinzi G, Colleredo G, Baiocchi L, Colombo S, Portincasa P, Coco B, Missale G, Marra F, Mattalia A, Giannini E, Abenavoli L, Picciotto A, Bollani S, Toniutto P, Gaudio E, Ronca V, Cristoferi L, Bonato G, Cordell HJ, Hirschfield GM, Alexander GJ, Sandford RN, Stocken DD, Jones DEJ, Invernizzi P*, Mells GF* for the Italian PBC Study Group & UK-PBC Consortium. Early patient stratification to enable personalized management of patients with primary biliary cholangitis. Lancet Gastroenterology & Hepatology 2018; 3:626-634.
  • Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018; 67:1568-1594.
  • Jopson L, Khanna A, Peterson P, Rudell E, Corrigan M, Jones DEJ. Are Clinicians Ready for Safe Use of Stratified Therapy in Primary Biliary Cholangitis (PBC)? A Study of Educational Awareness Dig Dis Sci. 2018; 63:2547-2554.
  • Probert PM, Leitch AC, Dunn MP, Meyer SK, Palmer JM, Abdelghany TM, Lakey AF, Cooke MP, Talbot H, Wills C, McFarlane W, Blake LI, Rosenmai AK, Oskarsson A, Figueiredo R, Wilson C, Kass GE, Jones DEJ, Blain PG, Wright MC. Identification of a xenobiotic as a potential environmental trigger in primary biliary cholangitis. J Hepatol 2018; 69:1123-1135.
  • Darlay R, Ayers KL, Mells GF, Hall LS, Liu JZ, Almarri MA, Alexander GJ, Jones DEJ, Sandford RN, Anderson CA, Cordell HJ. Amino acid residues in five separate HLA genes can explain most of the known associations between the MHC and primary biliary cholangitis. PLoS Genet. 2018 14:e1007833.
  • Liaskou E, Patel SR, Webb G, Bagkou Dimakou D, Akiror S, Krishna M, Mells G, Jones DEJ, Bowman SJ, Barone F, Fisher BA, Hirschfield GM. Increased sensitivity of Treg cells from patients with PBC to low dose IL-12 drives their differentiation into IFN-γ secreting cells. J Autoimmun 2018; 94:143-155.
  • Carbone M, Harms MH, Lammers WJ, Marmon T, Pencek R, MacConell L, Shapiro D, Jones DEJ, Mells GF, Hansen BE. Clinical Application of the GLOBE and UK-PBC Risk Score in a Trial Cohort of Patients with Primary Biliary Cholangitis. Hepatol Comm 2018; 2:683-692.
  • European Association for the Study of the Liver. EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol 2017; 67:145-172.
  • Hegade VS, Krawczyk M, Kremer AE, Kuczka J, Gaouar F, Kuiper EM, van Buuren HR, Lammert F, Corpechot C, Jones DEJ. The safety and efficacy of nasobiliary drainage in the treatment of refractory cholestatic pruritus: a multicentre European study. Aliment Pharmacol Ther 2016; 43:294-302.
  • Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P, Williamson KD; UK-PBC Consortium, Wareham NJ, Aldersley M, Bathgate A, Burroughs AK, Heneghan MA, Neuberger JM, Thorburn D, Hirschfield GM, Cordell HJ, Alexander GJ, Jones DEJ, Sandford RN, Mells GF. The UK-PBC Risk Scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology 2016; 60:930-950.
  • Hallsworth K, Jopson L, Jones DEJ, Trenell MI. Exercise therapy in primary biliary cirrhosis: the importance of moving while sitting on a surgical waiting list-a case study Frontline Gastroenterol. 2016; 7:167-169
  • Hegade VS, Khanna A, Walker LJ, Wong LL, Dyson JK, Jones DEJ Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score. Dig Dis Sci 2016; 61:3037-3041.
  • Grover VP, Southern L, Dyson JK, Kim JU, Crossey MM, Wylezinska-Arridge M, Patel N, Fitzpatrick JA, Bak-Bol A, Waldman AD, Alexander GJ, Mells GF, Chapman RW, Jones DEJ, Taylor-Robinson SD. Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging. Aliment Pharmacol Ther. 2016; 44:936-945.
  • Dyson JK, Wilkinson N, Jopson L, Mells G, Bathgate A, Heneghan MA, Neuberger J, Hirschfield GM, Ducker SJ; UK-PBC Consortium., Sandford R, Alexander G, Stocken D, Jones DEJ. The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2016; 44:1039-1050.
  • Hardie C, Green K, Jopson L, Millar B, Innes B, Pagan S, Tiniakos D, Dyson J, Haniffa M, Bigley V, Jones DEJ, Brain J, Walker LJ. Early molecular stratification of high-risk Primary Biliary Cholangitis. EBioMedicine. 2016; 14:65-73.
  • Trivedi PJ, Corpechot C, Pares A, Hirschfield GM. Risk Stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists Hepatology. 2015
  • Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D, Qian DC, Floyd JA, Morley KI, Prati D, Lleo A, Cusi D; Canadian-US PBC Consortium; Italian PBC Genetics Study Group; UK-PBC Consortium, Gershwin ME, Anderson CA, Lazaridis KN, Invernizzi P, Seldin MF, Sandford RN, Amos CI, Siminovitch KA. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways. Nat Commun. 2015; 6:8019.
  • Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon S, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr, Pares A, Trauner M, Marschall HU, Adorini L, Sciacca C, Beecher-Jones T, Castelloe E, Bohm O, Shapiro D. Efficacy of Obeticholic Acid in Patients with Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid Gastroenterology. 2014
  • Carbone M, Mells G, Pells G, Dawas MF, Newton JL, Heneghan M, Neuberger JM, Day D, Ducker SJ, UK-PBC Research Consortium, Sandford R, Alexander G, Jones DEJ. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology 2013; 144:560-569.
  • Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, Ponsioen CY, Floreani A, Copechot C, Mayo MJ, Battezzati PM, Pares A, Nevens F, Burroughs AK, Kowd;ey KV, Trivedi PJ, Kumagi T, Cheung A, Lleo A, Imam MH, Boonstra K, Cazzagon N, Franceschet I, Poupon R, Caballeria L, Pieri G, Kanwar PS, Lindor KD, Hansen BE, Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;147(6):1338-1349
  • Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, Jones DE. Health related quality of life in people with advanced chronic liver disease. Journal of Hepatology. 2014;61(5):1158-65
  • Lleo A, Zhang W, McDonald WH, Seeley EH, Leung PS, Coppel RL, Ansari AA, Adams DH, Afford S, Invernizzi P, Gershwin ME. Shotgun proteomics: identification of unique protein profiles of apoptotic bodies from biliary epithelial cells. Hepatology. 2014; 60(4):1314-23
  • Webb GJ, Hirschfield GM. Follicles, germinal centres and immune mechanisms in primary biliary cirrhosis. Hepatology. 2014
  • Afford SC, Humphreys EH, Reid DT, Russell CL, Banz VM, Oo Y, Vo T, Jenne C, Adams DH, Eksteen B. Vascular cell adhesion molecule 1 expression by biliary epithelium promotes persistence of imflammation by inhibiting effector T-cell apoptosis. Hepatology. 2014;59(5):1932-43
  • Dyson JK, Webb G, Hirschfield GM, Lohse A, Beuers U, Lindor K, Jones DE. Unmet clinical need in autoimmune liver diseases. Journal of Hepatology. 2014
  • Mells G, Pells G, Newton JL, Bathgate A, Burroughs A, Heneghan M, Neuberger J, Day D, Ducker SJ; The UK-PBC Consortiums, Sandford R, Alexander G, Jones DEJ The impact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study. Hepatology 2013; 58:273-283.
  • Pells G, Mells GF, Carbone M, Newton JL, Bathgate AJ, Burroughs AK, Heneghan MA, Neuberger JM, Day DB, Ducker SJ, Sandford RN, Alexander GJ, Jones DEJ. The impact of liver transplantation on the phenotype of Primary Biliary Cirrhosis patients in the UK-PBC Cohort. J Hepatol 2013; 59:67-73.
  • Carbone M, Bufton S, Monaco A, Griffiths L, Jones DEJ, Neuberger JM. The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: A prospective study. J Hepatol 2013; 59:490-494.
  • Brain JG, Robertson H, Thompson E, Humphreys EH, Gardner A, Booth TA, Jones DE, Afford SC, von Zglinicki T, Burt AD, Kirby JA. Biliary epithelial senescence and plasticity in acute cellular rejection. American Journal of Transplantation. 2013;13(7):1688-702.
  • Mells GF, Hirschfield GM. Genetics of Primary Biliary Cirrhosis. eLS. Chichester: John Wiley & Sons; 2013
  • Hirschfield GM, Gershwin ME. The Immunobiology and Pathophysiology of Primary Biliary Cirrhosis. Annu Rev Pathol-Mech. 2013;8:303-30
  • Carbone M, Mells GF, Alexander GJ, Westbrook RH, Heneghan MA, Sandford RN, Neuberger JM. Calcineurin inhibitors and the IL12A locus influence risk of recurrent primary biliary cirrhosis after liver transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013;13(4):1110-1
  • Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, Ducker S, Day D, Heneghan MA, Neuberger JM, Donaldosn PT, Bathgate A, Burroughs A, Davies M, Jones DEJ, Alexander GJ, Barrett JC, The UK-PBC Consortium, The Wellcome Trust case Control Consortium 3, Sandford RN, Anderson CA. Dense fine-mapping study identifies novel disease loci and implicates coding and non-coding variation in primary biliary cirrhosis risk. Nature Genetics 2012; 44:1137-1141.
  • Patanwala I, Walton R, Mells G, Newton J, Alexander G, Hudson M, Jones D. The Clinical Impact of Varices and a New Externally Validated Non-Invasive Inexpensive Tool to Predict Their Presence in Patients with PBC. Journal of hepatology. 2012;56:S380-S
  • Mells G, Alexander G, Jones D, Sandford R, Cordell H, UK-PBC Consortium. Pathway Analysis of the UK GWAS Dataset Implicates Key Immunoregulatory Pathways in the Pathogenesis of Primary Biliary Cirrhosis. Journal of Hepatology. 2012;56:S377-S8
  • Liu JZ, Almarri MA, Gaffney DJ, Mells GF, Jostins L, Cordell HJ, Ducker SJ, Day DB, Heneghan MA, Neuberger JM, Donaldson PT, Bathgate AJ, Burroughs A, Davies MH, Jones DE, Alexander GJ, Barrett JC, Sandford RN, Anderson CA, UK-PBC Consortium, Wellcome Trust Case Control Consortium. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis. Nature Genetics. 2012;44(10):1137-41
  • Jones DE, Mells G. The genetics of primary biliary cirrhosis: the revolution moves on. Hepatology. 2011;53(1):362-4
  • Mells, GF, Floyd JAB, Morley KI, Cordell HJ, Franklin CS, Shin S-Y, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, Ducker SJ, Muriithi AW, Wheater EF, Hammond C, Dawwas M, The UK PBC Consortium, Wellcome Trust CCC, Jones DEJ, Peltonen L, Alexander GJ, Sandford RN, Anderson CA. Genome-wide association study identifies 13 additional susceptibility loci for primary biliary cirrhosis. Nature Genetics 2011; 43:329-332.

UK-PBC Trial Platform Papers

  • Schattenberg JM, Pares A, Kowdley KV, Heneghan MA, Caldwell S, Pratt D, Bonder A, Hirschfield GM, Levy C, Vierling J, Jones DEJ, Tailleux A, Staels B, Megnien S, Hanf R, Magrez D, Birman P, Luketic V. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. J Hepatol 2021; In press
  • Mayo ML, Pockros PJ, Jones DEJ, Bowlus CL, Levy C, Patanwala I, Bacon B, Luketic V, Vuppalanchi R, Medendorp S, Dorenbaum A, Kennedy C, Novak P, Gu J, Apostol G, Hirschfield GM. A randomized, controlled phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Comm 2019; 3:365-381.
  • Khanna A, Jopson L, Howel D, Bryant A, Blamire A, Newton JL, Jones DEJ Rituximab is Ineffective for Treatment of Fatigue in Primary Biliary Cholangitis: A phase-2 Randomised Controlled Trial. Hepatology 2019; 70:1646-1655
  • de Graaf K, Lapeyre G, Guilhot F, Ferlin Walter, Curbishley S, Carbone M, Richardson P, Hayes P, Moreea S, McCune C, Ryder S, Chapman R, Floreani A, Jones DEJ, de Min C, Adams DH, Invernizzi P. NI-0801, an anti-CXCL10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Hepatol Comm 2018; 2:492-453.
  • Khanna A, Jopson L, Howel D, Bryant A, Blamire A, Newton JL, Wilkinson J, Steel AJ, Bainbridge J, Stefanetti R, Cassidy S, Houghton D, Jones DEJ. Rituximab for the treatment of fatigue in primary biliary cholangitis (formerly primary biliary cirrhosis): a randomised controlled trial. NIHR Journals Library 2018 April
  • Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Parés A, Mason A, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, Böhm O, Pencek R, Jones DEJ. A Randomized Trial of Obeticholic Acid Monotherapy in Patients with Primary Biliary Cholangitis. Hepatology 2018; 67:1890-1902.
  • Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Thompson D, Richards D, Storey J, Dukes GE, Corrigan M, Oude Elferink RP, Beuers U, Hirschfield GM, Jones DEJ. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study. Lancet. 2017; 389:1114-1123.
  • Jones DEJ, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study. Lancet Gastroenterology & Hepatology. 2017; 2:716-726.
  • Nevens F, Andreone P, Mazzella G, Strasser S, Bowlus C, Invernizzi P, Drenth J, Pockros P, Regula J, Beuers U, Trauner M, Jones DEJ, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum K, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall H-U, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D for the POISE Study Group*. Obeticholic Acid in Primary Biliary Cholangitis / Cirrhosis: A Phase 3 Trial. New England Journal of Medicine 2016; 375:631-643.
  • Hirschfield GM, Gershwin ME, Strauss R, Mayo MJ, Levy C, Zou B, Johanns J, Nnane IP, Dasgupta B, Li K, Selmi C, Marschall HU, Jones DEJ, Lindor K; PURIFI Study Group. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to Ursodeoxycholic Acid: a proof-of-concept study. Hepatology 2016; 64:189-99.
  • Hegade VS, Kendrick SF, Dobbins RL, Miller SR, Richards D, Storey J, Dukes G, Gilchrist K, Vallow S, Alexander GJ, Corrigan M, Hirschfield GM, Jones DEJ BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial BMC Gastroenterol. 2016; 16:71
  • Jopson L, Newton JL, Palmer J, Floudas A, Isaacs J, Qian J, Wilkinson J, Trenell M, Blamire A, Howel D, Jones DEJ. RITPBC: B-cell depleting therapy (rituximab) as a treatment for fatigue in primary biliary cirrhosis: study protocol for a randomised controlled trial. BMJ Open 2015; e007985.

Editorials, Reviews and Other Linked Publications

  • Dyson JK & Jones DEJ. Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management? Gastroenterology 2021; In press
  • Jones DEJ & Dyson JK. “Primary Biliary Cholangitis”. In Firth J, Cox T, and Conlon C (Editors). Oxford Textbook of Medicine, 6th Edition. Oxford University Press 2020.
  • McMeekin P, Lendrem DW, Lendrem BC, Pratt AG, Peck R, Isaacs JD, Jones DEJ. Schrödinger’s pipeline and the outsourcing of pharmaceutical innovation. Drug Discov Today. 2020;25:480-484.
  • Phaw NA, Dyson JK, Jones DEJ. Emerging drugs for the treatment of primary biliary cholangitis. Expert Opin Emerg Drugs 2020; 25:101-112.
  • Dyson JK & Jones DEJ. UDCA Prophylaxis for Post-Transplant PBC Recurrence Prevention: Time to Change Practice. J Hepatol 2020; 73:499-501
  • Alrubaiy L, Mells G, Flack S, Bosomworth H, Hutchings H, Williams J, Jones DEJ Editorial: rapid assessment of health-related quality of life in primary biliary cholangitis-no excuse not to ask. Authors’ reply. Aliment Pharmacol Ther 2020 51:183.
  • Terziroli Beretta-Piccoli B, Mieli-Vergani G, Vergani D, Vierling JM, Adams D, Alpini G, Banales JM, Beuers U, Björnsson E, Bowlus C, Carbone M, Chazouillères O, Dalekos G, De Gottardi A, Harada K, Hirschfield G, Invernizzi P, Jones DEJ, Krawitt E, Lanzavecchia A, Lian ZX, Ma X, Manns M, Mavilio D, Quigley EM, Sallusto F, Shimoda S, Strazzabosco M, Swain M, Tanaka A, Trauner M, Tsuneyama K, Zigmond E, Gershwin ME. The challenges of primary biliary cholangitis: What is new and what needs to be done. J Autoimmun 2019; 105:102328
  • Jones DEJ, Hegade VS. Bezafibrate in Primary Biliary Cholangitis. N Engl J Med 2018; 379:98.
  • Jones DEJ. Primary Biliary Cholangitis. In Dooley JS, Lok ASF, Garcia-Tsao G, Pinzani M (Editors) Sherlock’s Diseases of the Liver & Biliary System 13th Edition. Wiley;2018.
  • Mells GF, Jones DEJ. Stratified medicine and Primary Biliary Cholangitis. Lancet Gastroenterol Hepatol 2017; 2:319-321.
  • Mells GF, Jones DEJ. Scoring systems in Primary Biliary Cholangitis-time to make a move. Aliment Pharmacol Ther 2017; 45:1163-1164
  • Wong LL, Hegade VS, Jones DEJ. What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis 2017 35:359-366.
  • Khanna A, Jones DEJ. Novel strategies and therapeutic options for the management of primary biliary Cholangitis. Therap Adv Gastroenterol. 2017; 10:791-803.
  • Nevens F, Lindor KD, Jones DEJ. Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med 2016; 375:17.
  • Jones DEJ, Hansen B. Fenofibrate as second-line therapy in high risk PBC – more answers or more questions? Aliment Pharmacol Ther. 2016; 43:648-9.
  • Hegade VS, Speight RA, Etherington RE, Jones DEJ. Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol. 2016 May; 9:376-91.
  • Jones DEJ. Obeticholic acid for the treatment of primary biliary cirrhosis. Expert Rev Gastroenterol Hepatol. 2016; 2:1-9.
  • Dyson JK, Hirschfield D, Beuers U, Adams D, Lindor K Jones DEJ. Novel treatment targets in primary biliary cirrhosis. Nature Gastroenterol Hepatol 2015; 12:147-158.
  • Dyson JK, Webb G, Hirschfield G, Beuers U, Lohse A, Lindor KD, Jones DEJ. Unmet need in autoimmune liver disease. J Hepatol 2015; 68:208-218
  • Hirschfield GM, Thain C, Walmsley M, Brownlee A, Jones DEJ. Liver disease in the UK. Lancet 2015; 385:503.
  • Beuers U, Gershwin ME, Gish RG, Invernizzi P, Jones DEJ, Lindor K, Ma X, Mackay IR, Parés A, Tanaka A, Vierling JM, Poupon R. Changing nomenclature for PBC: From ‘cirrhosis’ to ‘cholangitis’
    Clin Res Hepatol Gastroenterol 2015; 39:57-59.
    Dig Liver Dis 2015; 47:924-926.
    Am J Gastroenterol 2015; 110:1536-1538
    Clin Gastroenterol Hepatol 2015; 13:1867-1869
    J Hepatol 2015; 63:1285-1287.
    Gastroenterology 2015; 149:1627-1629.
    Gut. 2015; 64:1671-1672
    Hepatology 2015; 62:1620-1622.
  • Carbone M, Bufton S, Jones DEJ, Neuberger JM. Fatigue and liver transplantation in patients with primary biliary cirrhosis. J Hepatol 2014; 60:1328-1329.
  • Dyson JK, Jones DEJ. Diagnosis and management of patients with Primary Biliary Cirrhosis. Clinical Liver Disease 2014; 3:52-55.
  • Griffiths L, Dyson JK, Jones DEJ. The new epidemiology of Primary Biliary Cirrhosis. Semin Liver Dis 2014; 34:318-328.
  • Griffiths L, Jones DEJ Pathogenesis of primary biliary cirrhosis and its fatigue. Dig Dis 2014; 32:615-625.